Tag: Protocol

Posted on by — Leave a comment

Semax 10mg Dosage Protocol

Preparation & Measurement Guide

Semax 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Semax 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Semax 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
300-750mcg once daily

1. Preparation and Measurement

Semax 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 300mcg once daily 0.06mL / 6 units
Weeks 3-4 500mcg once daily 0.1mL / 10 units
Weeks 5-8 750mcg once daily 0.15mL / 15 units

Vial estimate: One 10mg vial contains approximately 33 administrations at the first listed amount or 13 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Semax 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Semax has been studied in experimental models involving neurotrophic signalling, oxidative stress, and ischemic injury. Published work includes other formulations and routes that are not interchangeable with a prepared research vial.

Semax is not an approved therapeutic drug in Canada or the United States. No clinically validated schedule exists for this research material.

Primary Research and Regulatory References

  1. Semax neurotrophic-factor expression study
  2. Semax experimental ischemia study

Research Materials

Review Semax 10mg Product Information

View Semax 10mg
Browse Cognitive Research

← Back to Dosage Protocols

Research-use disclaimer: Semax 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

SS-31 10mg Dosage Protocol

Preparation & Measurement Guide

SS-31 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a SS-31 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
SS-31 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
5-15mg once daily

1. Preparation and Measurement

SS-31 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 5mg once daily 1mL / 100 units
Weeks 3-4 10mg once daily 2mL / 200 units*
Weeks 5-8 15mg once daily 3mL / 300 units*

Vial estimate: One 10mg vial contains approximately 2 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • SS-31 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

SS-31, also studied as elamipretide, targets mitochondrial membranes and has been evaluated in preclinical models and human trials. Clinical results have been mixed, and trial formulations cannot be assumed equivalent to research material.

SS-31 is not approved for general therapeutic use. The table records a circulated convention and is not a clinical recommendation.

Primary Research and Regulatory References

  1. Elamipretide MMPOWER-3 clinical trial
  2. Elamipretide dose-escalation study
  3. SS-31 mitochondrial mechanism study

Research Materials

Review SS-31 10mg Product Information

View SS-31 10mg
Browse Longevity and Cellular Research

← Back to Dosage Protocols

Research-use disclaimer: SS-31 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

SS-31 50mg Dosage Protocol

Preparation & Measurement Guide

SS-31 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a SS-31 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
SS-31 50mg
Preparation
2mL bacteriostatic water
Concentration
25mg/mL after preparation
Documented Convention
5-15mg once daily

1. Preparation and Measurement

SS-31 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL
1 U-100 unit = 0.01mL = 250mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 5mg once daily 0.2mL / 20 units
Weeks 3-4 10mg once daily 0.4mL / 40 units
Weeks 5-8 15mg once daily 0.6mL / 60 units

Vial estimate: One 50mg vial contains approximately 10 administrations at the first listed amount or 3 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • SS-31 50mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

SS-31, also studied as elamipretide, targets mitochondrial membranes and has been evaluated in preclinical models and human trials. Clinical results have been mixed, and trial formulations cannot be assumed equivalent to research material.

SS-31 is not approved for general therapeutic use. The table records a circulated convention and is not a clinical recommendation.

Primary Research and Regulatory References

  1. Elamipretide MMPOWER-3 clinical trial
  2. Elamipretide dose-escalation study
  3. SS-31 mitochondrial mechanism study

Research Materials

Review SS-31 50mg Product Information

View SS-31 50mg
Browse Longevity and Cellular Research

← Back to Dosage Protocols

Research-use disclaimer: SS-31 50mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

TB-500 10mg Dosage Protocol

Preparation & Measurement Guide

TB-500 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a TB-500 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
TB-500 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
500mcg-1mg once daily

1. Preparation and Measurement

TB-500 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 500mcg once daily 0.1mL / 10 units
Weeks 3-4 750mcg once daily 0.15mL / 15 units
Weeks 5-8 1mg once daily 0.2mL / 20 units

Vial estimate: One 10mg vial contains approximately 20 administrations at the first listed amount or 10 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • TB-500 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

TB-500 is associated with thymosin beta-4 research involving cell migration, wound models, and tissue repair. Commercial TB-500 material should not be assumed identical to full-length thymosin beta-4 used in published studies.

TB-500 is not an approved therapeutic drug. No clinically validated dosing schedule has been established.

Primary Research and Regulatory References

  1. Thymosin beta-4 wound-healing research
  2. Thymosin beta-4 cell-migration study
  3. Thymosin beta-4 repair research review

Research Materials

Review TB-500 10mg Product Information

View TB-500 10mg
Browse Recovery and Repair

← Back to Dosage Protocols

Research-use disclaimer: TB-500 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Retatrutide 40mg Dosage Protocol

Preparation & Measurement Guide

Retatrutide 40mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 40mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Retatrutide 40mg
Preparation
2mL bacteriostatic water
Concentration
20mg/mL after preparation
Documented Convention
2-12mg once weekly

1. Preparation and Measurement

Retatrutide 40mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 20mg/mL. On a U-100 syringe, each unit contains 200mcg.

40mg / 2mL = 20mg/mL
1 U-100 unit = 0.01mL = 200mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.1mL / 10 units
Weeks 5-8 4mg once weekly 0.2mL / 20 units
Weeks 9-12 8mg once weekly 0.4mL / 40 units
Weeks 13+ 12mg once weekly 0.6mL / 60 units

Vial estimate: One 40mg vial contains approximately 20 administrations at the first listed amount or 3 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 40mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 40mg Product Information

View Retatrutide 40mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 40mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Retatrutide 5mg Dosage Protocol

Preparation & Measurement Guide

Retatrutide 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Retatrutide 5mg
Preparation
1mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
2-12mg once weekly

1. Preparation and Measurement

Retatrutide 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 1mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.4mL / 40 units
Weeks 5-8 4mg once weekly 0.8mL / 80 units
Weeks 9-12 8mg once weekly 1.6mL / 160 units*
Weeks 13+ 12mg once weekly 2.4mL / 240 units*

Vial estimate: One 5mg vial contains approximately 2 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

  • The table applies only to this vial prepared with exactly 1mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 5mg vial.
  • 1mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 5mg Product Information

View Retatrutide 5mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 5mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Selank 10mg Dosage Protocol

Preparation & Measurement Guide

Selank 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Selank 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Selank 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
300-500mcg once daily

1. Preparation and Measurement

Selank 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 300mcg once daily 0.06mL / 6 units
Weeks 3-4 500mcg once daily 0.1mL / 10 units

Vial estimate: One 10mg vial contains approximately 33 administrations at the first listed amount or 20 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Selank 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Selank has limited human literature and additional animal work involving anxiety-related measures and GABAergic signalling. Some clinical literature used intranasal formulations, so it does not validate a reconstituted vial convention.

Selank is not an approved therapeutic drug in Canada or the United States. The table is an educational record of a circulated convention.

Primary Research and Regulatory References

  1. Selank generalized-anxiety clinical comparison
  2. Selank and GABAergic gene-expression study

Research Materials

Review Selank 10mg Product Information

View Selank 10mg
Browse Cognitive Research

← Back to Dosage Protocols

Research-use disclaimer: Selank 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Semaglutide 10mg Dosage Protocol

Preparation & Measurement Guide

Semaglutide 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Semaglutide 10mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.
Vial Size
Semaglutide 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
0.25-2.4mg once weekly

1. Preparation and Measurement

Semaglutide 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 0.25mg once weekly 0.05mL / 5 units
Weeks 5-8 0.5mg once weekly 0.1mL / 10 units
Weeks 9-12 1mg once weekly 0.2mL / 20 units
Weeks 13-16 1.7mg once weekly 0.34mL / 34 units
Weeks 17+ 2.4mg once weekly 0.48mL / 48 units

Vial estimate: One 10mg vial contains approximately 40 administrations at the first listed amount or 4 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Semaglutide 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Semaglutide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents one approved weight-management titration as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated pen or vial.

Primary Research and Regulatory References

  1. FDA Wegovy prescribing information
  2. STEP 1 semaglutide body-composition analysis
  3. Semaglutide weight-management clinical trial

Research Materials

Review Semaglutide 10mg Product Information

View Semaglutide 10mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Semaglutide 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Semaglutide 20mg Dosage Protocol

Preparation & Measurement Guide

Semaglutide 20mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Semaglutide 20mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.
Vial Size
Semaglutide 20mg
Preparation
2mL bacteriostatic water
Concentration
10mg/mL after preparation
Documented Convention
0.25-2.4mg once weekly

1. Preparation and Measurement

Semaglutide 20mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

20mg / 2mL = 10mg/mL
1 U-100 unit = 0.01mL = 100mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 0.25mg once weekly 0.025mL / 2.5 units
Weeks 5-8 0.5mg once weekly 0.05mL / 5 units
Weeks 9-12 1mg once weekly 0.1mL / 10 units
Weeks 13-16 1.7mg once weekly 0.17mL / 17 units
Weeks 17+ 2.4mg once weekly 0.24mL / 24 units

Vial estimate: One 20mg vial contains approximately 80 administrations at the first listed amount or 8 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Semaglutide 20mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Semaglutide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents one approved weight-management titration as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated pen or vial.

Primary Research and Regulatory References

  1. FDA Wegovy prescribing information
  2. STEP 1 semaglutide body-composition analysis
  3. Semaglutide weight-management clinical trial

Research Materials

Review Semaglutide 20mg Product Information

View Semaglutide 20mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Semaglutide 20mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

NAD+ 500mg Dosage Protocol

Preparation & Measurement Guide

NAD+ 500mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a NAD+ 500mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
NAD+ 500mg
Preparation
2mL bacteriostatic water
Concentration
250mg/mL after preparation
Documented Convention
50-100mg once daily

1. Preparation and Measurement

NAD+ 500mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 250mg/mL. On a U-100 syringe, each unit contains 2.5mg.

500mg / 2mL = 250mg/mL
1 U-100 unit = 0.01mL = 2.5mg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: once daily.

Period Documented amount Measurement
Week 1 50mg once daily 0.2mL / 20 units
Week 2 75mg once daily 0.3mL / 30 units
Weeks 3-4 100mg once daily 0.4mL / 40 units

Vial estimate: One 500mg vial contains approximately 10 administrations at the first listed amount or 5 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • NAD+ 500mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

NAD+ is a central metabolic cofactor. Direct human studies have primarily examined intravenous infusion and metabolite handling, not the subcutaneous convention shown here.

Evidence for injected NAD+ remains limited, and published intravenous findings cannot validate a different route, concentration, or schedule.

Primary Research and Regulatory References

  1. Human intravenous NAD+ metabolome pilot study
  2. Intravenous NAD+ tolerability pilot study
  3. NAD+ metabolism and aging review

Research Materials

Review NAD+ 500mg Product Information

View NAD+ 500mg
Browse Longevity and Cellular Research

← Back to Dosage Protocols

Research-use disclaimer: NAD+ 500mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

PT-141 10mg Dosage Protocol

Preparation & Measurement Guide

PT-141 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a PT-141 10mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.
Vial Size
PT-141 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
1.75mg per documented event

1. Preparation and Measurement

PT-141 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in the approved comparator formulation. Frequency: no more than once in 24 hours in the comparator label.

Period Documented amount Measurement
Documented approved-drug comparator 1.75mg single dose at least 45 minutes before the studied event 0.35mL / 35 units

Vial estimate: One 10mg vial contains approximately 5 documented-size administrations at 1.75mg.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • PT-141 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Bremelanotide is the active molecule in an approved prescription product with formulation-specific instructions, contraindications, and limits. That approval does not transfer to a laboratory vial.

The table reproduces the approved product’s amount only as a documented comparator. This research material is not the approved drug product and is not interchangeable with it.

Primary Research and Regulatory References

  1. Bremelanotide phase 3 clinical trials
  2. Bremelanotide dose-finding study
  3. FDA Vyleesi prescribing information

Research Materials

Review PT-141 10mg Product Information

View PT-141 10mg
Browse All Peptides

← Back to Dosage Protocols

Research-use disclaimer: PT-141 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Retatrutide 10mg Dosage Protocol

Preparation & Measurement Guide

Retatrutide 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Retatrutide 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
2-12mg once weekly

1. Preparation and Measurement

Retatrutide 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.4mL / 40 units
Weeks 5-8 4mg once weekly 0.8mL / 80 units
Weeks 9-12 8mg once weekly 1.6mL / 160 units*
Weeks 13+ 12mg once weekly 2.4mL / 240 units*

Vial estimate: One 10mg vial contains approximately 5 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 10mg Product Information

View Retatrutide 10mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.